MACROGENICS, INC. Common Stock, Value, Issued
MACROGENICS, INC. (MGNX) had Common Stock, Value, Issued of $637.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:CommonStockValue · last filed 2026-08-14
- 2026-06-30: Common Stock, Value, Issued $637.00K.
- 2026-03-31: Common Stock, Value, Issued $636.00K.
- 2025-12-31: Common Stock, Value, Issued $633.00K.
- 2025-09-30: Common Stock, Value, Issued $633.00K.
| Period end | Common Stock, Value, Issued | Common Stock, Value, Issued as first filed |
|---|---|---|
| 2026-06-30 | $637.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $636.00K 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $633.00K 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $633.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $632.00K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $631.00K 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $628.00K 10-K · filed 2026-03-09 | |
| 2024-09-30 | $627.00K 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $627.00K 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $626.00K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $621.00K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $620.00K 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $619.00K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $618.00K 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $617.00K 10-K · filed 2024-03-07 | |
| 2022-09-30 | $615.00K 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $615.00K 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $613.00K 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $613.00K 10-K · filed 2023-03-15 | |
| 2021-09-30 | $613.00K 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $601.00K 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $600.00K 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $562.00K 10-K · filed 2022-02-24 | |
| 2020-09-30 | $562.00K 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $534.00K 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $492.00K 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $490.00K 10-K · filed 2021-02-25 | |
| 2019-09-30 | $489.00K 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $489.00K 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $488.00K 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $424.00K 10-K · filed 2020-02-25 | |
| 2018-09-30 | $422.00K 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $422.00K 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $370.00K 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $369.00K 10-K · filed 2019-02-26 | |
| 2017-09-30 | $368.00K 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $367.00K 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $350.00K 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $349.00K 10-K · filed 2018-02-27 | |
| 2016-09-30 | $348.00K 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $347.00K 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $345.00K 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $343.00K 10-K · filed 2017-02-28 | |
| 2015-09-30 | $342.00K 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $301.00K 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $300.00K 10-Q · filed 2015-05-06 | |
| 2014-12-31 | $280.00K 10-K · filed 2016-02-29 | |
| 2014-09-30 | $278.00K 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $277.00K 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $274.99K 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $252.00K 10-K · filed 2015-03-03 | $251.78K 10-K · filed 2014-03-20 |
| 2013-09-30 | $21.25K 10-Q · filed 2013-11-12 | |
| 2012-12-31 | $10.99K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |